financetom
Business
financetom
/
Business
/
LNG Energy Group Down 6.5% as it Reports a Fourth-Quarter Loss, Sales of US$9.5 Million
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
LNG Energy Group Down 6.5% as it Reports a Fourth-Quarter Loss, Sales of US$9.5 Million
Apr 30, 2024 8:50 AM

11:27 AM EDT, 04/30/2024 (MT Newswires) -- LNG Energy Group ( LNGNF ) was last seen down 6.5% after the company on Tuesday reported a fourth-quarter loss of US$19.6 million on sales of US$9.5 million.

The South American natural-gas producer said it lost US$1.1 million and sales of US$13.6 million, respectively since competing a reverse takeover of Mind Cure Health in August, 2023, and listing its shares in September of last year.

LNG reported production before royalties of 18,057 thousand cubic feet of natural gas per day and 193 barrels per day of condensate. The company said it has realized sales volumes before royalties of 17,931 mcfpd and 191 bpd condensate.

The company reported fourth-quarter operating netbacks of US$4.44 per thousand cubic feet of natural gas and US$64.75 per barrel of condensates.

The company also provided an update on its plans for Colombia and Venezuela in 2024.

For Colombia, the company expects to complete a workover and optimization program targeting four to six wells; drill one development well in the producing Bullerengue field in the Sinu-San Jacinto-1 Block; drill two to four exploration wells in the SSJN-1 and Perdices Blocks; continuing to evaluate and support the company's commitment to environmental, social and governance initiatives; and the repayment of its indebtedness and strengthening of its capital and liquidity resources.

In Venezuela, the company said it will assess the applicability of License 44A to its intended operations in Venezuela and determine the most appropriate course of action. LNG plans to operate in full compliance with the applicable sanction regimes.

The company's shares were last seen down C$0.025 to C$0.36 on the TSX Venture Exchange.

Price: 0.36, Change: -0.03, Percent Change: -6.49

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Capitol Federal Financial Keeps Quarterly Dividend at $0.085 a Share, Payable Feb. 21 to Holders of Record Feb. 7
--Capitol Federal Financial Keeps Quarterly Dividend at $0.085 a Share, Payable Feb. 21 to Holders of Record Feb. 7
Jan 28, 2025
11:14 AM EST, 01/28/2025 (MT Newswires) -- Price: 5.82, Change: +0.02, Percent Change: +0.26 ...
Medexus Pharmaceuticals Prices $30-Million Marketed Share Offering
Medexus Pharmaceuticals Prices $30-Million Marketed Share Offering
Jan 28, 2025
11:14 AM EST, 01/28/2025 (MT Newswires) -- Medexus Pharmaceuticals ( MEDXF ) , down 13% on last look, said it priced its overnight marketed underwritten offering of 7.5-million shares at $4.00 each to raise $30 million. The underwriters have been granted an over-allotment option of up to 1.13 million shares. Proceeds will be used to repay a US$2.5 million credit...
Montero Agrees To Distribution of US$27 Million Settlement From Tanzania
Montero Agrees To Distribution of US$27 Million Settlement From Tanzania
Jan 28, 2025
11:07 AM EST, 01/28/2025 (MT Newswires) -- Montero Mining and Exploration ( MXTRF ) on Monday said it finalized the distribution of the US$27 million settlement with its litigation funders, Omni Bridgeway (Canada). The settlement amount was agreed with Tanzania over the expropriation of Montero's Wigu Hill rare earth element project. The company said it has already paid Omni US$12...
Neurocrine Biosciences Begins Phase 3 Study of Osavampator in Major Depressive Disorder
Neurocrine Biosciences Begins Phase 3 Study of Osavampator in Major Depressive Disorder
Jan 28, 2025
11:10 AM EST, 01/28/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Tuesday that it started a phase 3 registrational study to evaluate the efficacy, safety, and tolerability of osavampator as an adjunctive treatment to antidepressants for major depressive disorder. The company said the study will enroll adults primarily diagnosed with major depressive disorder and have inadequate response to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved